Exalt Single-use Duodenoscope Vs Reusable Scope, a Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Number of attempts required to achieve successful cannulation of the desired duct
研究概览
简要总结
This randomized controlled trial (RCT) is designed to evaluate the new generation Exalt Model disposable duodenoscope compared to the reusable scope in terms of feasibility, ease of use, adverse events, number of crossover events, and infection rates.
详细描述
To ensure a safe and high-quality endoscopy, there are multiple disinfection protocols for endoscopes. Side-viewing duodenoscopes with an adjustable accessory device (elevator) contain potential blind spots for debris and bacteria that require specialized cleaning and disinfection methods beyond standard protocols for other endoscopes. It is thought that the duodenoscope's design, persistent postprocedural microbial contamination and biofilm formation make it more prone to cross-contamination5. Gromski et al, found there are documented pathogenic transmissions, which led to harm in multiple patients and centers3. Infection control was likely related to two major components, reusable duodenoscopes and procedural factors related to how the reusable duodenoscopes were reprocessed3. Multidrug-resistant organisms, such as carbapenem-resistant Enterobacteriaceae, that were associated with reusable duodenoscopes lead the FDA to mandate the transition to improved cleaning and disinfection methods or single-use platforms to eliminate infection transmission. One such single-use platform is the Exalt Model D (Boston Scientific, Marlboro, MA), which received FDA approval in 2020 for use of single-use duodenoscopes. Early iterations of the Exalt were used on a case-by-case basis per institution-specific protocols, mainly due to the learning curve involved with using the scope. A new version of Exalt has been released to market in 2023 with modifications that may make it more feasible to use in all settings requiring a duodenoscope. This randomized controlled trial (RCT) is designed to evaluate the new generation Exalt Model disposable duodenoscope compared to the reusable scope in terms of feasibility, ease of use, adverse events, number of crossover events, and infection rates.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 19 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients > 18 years old who have biliary or pancreatic duct disorder, based on clinical symptoms and radiological findings at CT or magnetic resonance cholangiopancreatography
- •Native papilla
排除标准
- •Patients with altered pancreaticobiliary anatomy
- •Pregnancy
- •Patients with percutaneous transhepatic biliary drainage
- •Prior history of ERCP
- •Inability to provide informed consent
结局指标
主要结局
Number of attempts required to achieve successful cannulation of the desired duct
时间窗: From the time of the ERCP to 7 days post-ERCP per standard of care
Measure and compare the total number of attempts required to achieve successful cannulation of the desired duct.
次要结局
- Crossover single to reusable(From the start of the ERCP to the end of procedure)
- Use of advanced cannulation techniques(From the start of the ERCP to the end of procedure)
- Performance on ERCP maneuvers(From the start of the ERCP to the end of procedure)
- Adverse events(From the completion of the ERCP to 7 days post-ERCP per standard of care)
- Endoscopist-determined ease of use(From the start of the ERCP to the end of procedure)
研究者
Neal Ambrish Mehta
Assistant Professor
Rush University Medical Center
